{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"56.492","value":"12.047"}]}],"title":"Everolimus (n=42)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"234.578","value":"0.657"}]}],"title":"Exemestane (n=48)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Blood samples were collected and analyzed.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.","id":"OG000","title":"Dexamethasone Based Mouthwash"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set, which was a subset of the FAS, was considered for the analysis. However, only participants who had evaluable data were analyzed.","reportingStatus":"POSTED","timeFrame":"28 days (pre-dose)","title":"Blood Concentration of Everolimus and Exemestane","type":"SECONDARY","unitOfMeasure":"ng/mL"}